Eledon Pharmaceuticals In...

AI Score

0

Unlock

3.86
0.15 (4.04%)
At close: Jan 15, 2025, 9:37 AM

Company Description

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.

The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.

Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc. logo
Country United States
IPO Date Sep 17, 2014
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Dr. David-Alexandre C. Gros M.D., Ph.D.

Contact Details

Address:
19900 MacArthur Boulevard
Irvine, California
United States
Website https://eledon.com

Stock Details

Ticker Symbol ELDN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001404281
CUSIP Number 28617K101
ISIN Number US28617K1016
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. David-Alexandre C. Gros M.D., Ph.D. Chief Executive Officer & Non Independent Director
Paul Sean Little Chief Financial Officer
Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. David Hovland Ph.D. Chief Regulatory Officer
Dr. Eliezer Katz F.A.C.S., FACS, M.D. Chief Medical Officer
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director
John Herberger Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing
Jan 13, 2025 4 Filing